Japan· JP-2499419D2022
テデュグルチド（遺伝子組換え）
A medicinal product containing テデュグルチド（遺伝子組換え）, registered in Japan by 武田薬品工業, on the national reimbursement list.
Checked against MHLW / PMDA (Japan) on
Informational only — not a medical device.
The record
At a glance
MHLW / PMDA (Japan)- Active substance
- テデュグルチド（遺伝子組換え）
- Manufacturer
- 武田薬品工業
- Country
- Japan (JP)
- ATC code
- —
- Reimbursed
- Yes
- Source register
- MHLW / PMDA (Japan)
- Last checked
- September 25, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
テデュグルチド（遺伝子組換え） in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- SwedenNilleto 5 mg Pulver och vätska till injektionsvätska, lösningFresenius Kabi AB
- FinlandRevestiveTakeda Pharmaceuticals International AG Ireland Branch
- CzechiaREVESTIVETakeda Pharmaceuticals International AG Ireland Branch, Dublin
- BelgiumRevestive 1.25 mgTakeda Pharmaceuticals International Ireland Branch
- SpainREVESTIVE 5 MG POLVO Y DISOLVENTE PARA SOLUCION INYECTABLETakeda Pharmaceuticals International Ag Ireland Branch
- IrelandRevestive 1.25 mg powder and solvent for solution for injectionTakeda Pharmaceuticals International AG Ireland Branch
- IcelandRevestiveTakeda Pharmaceuticals International AG Ireland Branch
- NetherlandsRevestive 1.25 mg, poeder en oplossing voor injectieTakeda Pharmaceuticals International AG Ireland Branch
Authorised across Europe · EMA
The same active substance is authorised in 7 EEA countries. Names it is sold under:
- Austria · Tidonalle
- Spain · Teduglutida Cipla
- France · Téduglutide, Teduglutide Adalvo
- Iceland · Revestive, Teduglutide Viatris
- Liechtenstein · Revestive, Teduglutide Viatris
- Norway · Niletto, Revestive
- Sweden · Nilleto, Teduglutid Cipla
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of MHLW / PMDA (Japan). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/d8cb5c74-b9f9-42b0-a428-9bae660edfe6 GET /v1/drugs/d8cb5c74-b9f9-42b0-a428-9bae660edfe6?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"spec": "０．９５ｍｇ１瓶（溶解液付）",
"marks": null,
"source": "mhlw",
"remarks": null,
"yj_code": "2499419D2022",
"category": "注射薬",
"price_yen": 18421,
"generic_name": "テデュグルチド（遺伝子組換え）",
"product_name_jp": null,
"therapeutic_class": "2499",
"transitional_expiry": null
}See everything about テデュグルチド（遺伝子組換え）.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.